Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $76.00.

Shares of Verona Pharma stock opened at $60.26 on Wednesday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. Verona Pharma has a twelve month ...

Summary The Chart of the Day belongs to biotechnology company Verona Pharma (VRNA) . I found the stock by using Barchart's ...

Verona Pharma plc (VRNA) stock price is 57.30 and Verona Pharma plc (VRNA) 10-day simple moving average is 54.54. Verona Pharma plc (VRNA) stock price is 57.30 and Verona Pharma plc (VRNA ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma. Looking at options history for Verona Pharma VRNA we detected 14 trades. If we consider the specifics ...

Verona Pharma has a 12-month low of $11.39 and a 12-month high of $55.91. The company has a market cap of $4.44 billion, a P/E ratio of -28.47 and a beta of 0.40.

Below is Validea's guru fundamental report for VERONA PHARMA PLC - ADR (VRNA). Of the 22 guru strategies we follow, VRNA rates highest using our Quantitative Momentum Investor model based on the ...

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The ...